Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05465616 · ClinicalTrials.gov registry record · NA
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
A NA study of Diabetes and PreDiabetes, sponsored by Viome.
- Recruiting
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT05465616: Recruiting NA study of Diabetes and PreDiabetes, sponsored by Viome.
NCT05465616 is a NA study of Diabetes and PreDiabetes that is actively recruiting participants, run by Viome. The registered enrollment target is 150 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05465616, a NA study of Diabetes and PreDiabetes, is actively recruiting participants, sponsored by Viome.
- RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, placebo-controlled trial that will test the efficacy of VPNP in reducing HbA1c. Participant recruitment will occur through direct-to-participant enrollment. No additional clinical sites will be used for recruitment.
Primary Outcome
HbA1c changes in individuals in the interventional arm compared to baseline measurement.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Viome's Precision Nutrition Program (VPNP)
Study Locations (1)
Washington
- Viome Life Sciences - Bothell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2022-08-22 |
| Est. Completion | 2026-12-13 |
| Phase | NA |
What NCT05465616 shows while recruiting
NCT05465616 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Viome's Precision Nutrition Program (VPNP) is the first listed.
NCT05465616 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT05465616 about?
NCT05465616 is a clinical study titled "Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c". This is a randomized, placebo-controlled trial that will test the efficacy of VPNP in reducing HbA1c. Participant recruitment will occur through direct-to-participant enrollment. No additional clinical sites will be used for recruitment.
What is the current status of trial NCT05465616?
This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2022-08-22. Estimated completion is 2026-12-13.
What conditions does trial NCT05465616 study?
This clinical trial studies the following conditions: Diabetes, PreDiabetes.
What interventions are being tested in trial NCT05465616?
The interventions under investigation include: Viome's Precision Nutrition Program (VPNP) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05465616?
This trial is sponsored by Viome, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05465616 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05465616's enrollment target sits among peer trials
150 165th of 338 higher than 168 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
Bringing Advocacy Via Digital Guide to the Emergency Department (Project BADGE)
RECRUITING · NA
-
Salud Diabetes: A Pilot Study Comparing Lifestyle Interventions and Real-Time Continuous Glucose Monitoring
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI